Atricure reports fourth quarter 2022 and full year 2022 financial results

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced fourth quarter 2022 and full year 2022 financial results. “we delivered another outstanding year of growth in 2022, as we expanded adoption across our broad portfolio of solutions.
ATRC Ratings Summary
ATRC Quant Ranking